Leukemia News ListMonday February 16, 2004 Ipsogen announces CE marking of its M-bcr FusionQuant™ assay.Marseille, France, February 16, 2004 - "Our M-bcr FusionQuant product is the first commercially available IVD assay in Europe for the quantification of the BCR-ABL gene, an acquired chromosomal abnormality occurring in... Category: Leukemia
 Saturday February 14, 2004 Ipsogen announces that the FDA / OPD qualified the MLL FusionChip™ for Humanitarian Use Device (HUD) designationIpsogen The MLL FusionChip ™ is an in vitro molecular diagnostic device utilizing an innovative biochip technology aimed at providing qualitative information on the gene fusion events between the MLL gene and its... Category: Leukemia
Friday February 06, 2004 Ipsogen announces an exclusive license in Europe from Genzyme Corporation to use the WT1 gene as a biomarker in acute LeukemiaMarseille, France, 2 “Several studies have shown that blood levels of Wilm’s tumour (WT1) can be used in Acute Myeloid Leukaemia (AML) at diagnosis to predict disease aggressiveness, determine patient response to treatment, and... Category: Leukemia
Displaying results 21 to 23 out of 23 |
|
